Detection within a Neuroendocrine Tumor of High Levels of B-Lymphocyte Stimulator (BLyS) Correlates with a Greater Disease Severity Abstract #1325

Introduction: .
Aim(s): Potential prognostic role of cytokine B-Lymphocyte Stimulator (BLyS) in follow-up of NET patients.
Materials and methods: 124 unselected patients (disease duration 5.9±4.4 yrs) with NET: 36 lung NET, 47 gastrointestinal NET and 41 pancreatic lesions. In 23 cases BLyS was repeatedly assessed during follow-up, the disease was monitored according to RECIST criteria. Patients were compared with a group of 77 healthy blood donors, matched for age and sex. Serum levels of BLyS and CgA were analyzed using ELISA.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr. Franco Grimaldi
Keywords: Tumor marker

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2213 Imaging Modality Depending on the Levels of Tumor Markers
Introduction: 18 F-Fluorodihydroxyphenylalanine(18F)-FDOPA positron emission tomography (PET)/computed tomography (CT) has the advantage of being a noninvasive test and is by far the most promising imaging modality for neuroendocrine tumors (NETs).
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: DOCTOR Julieta Iorio
Authors: Iorio J, Eleta M, Cuneo L, Polillo D, ...
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#404 B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Disease Behavior
Introduction: B-Lymphocyte Stimulator (BLyS) was recently involved in the regulation of malignant cell survival cancers.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Franco Grimaldi
#442 Low Diagnostic Accuracy of Tumor Markers for the Annual Screening of Pancreatic Neuroendocrine Tumors in MEN-1 Patients
Introduction: The use of tumor markers for annual screening for pancreatic neuroendocrine tumors (pNET) in Multiple Endocrine Neoplasia type 1 (MEN-1) is debatable because of low-level evidence and high costs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD PhD Gerlof Valk
#1044 Trends in Neuroendocrine Tumor in Friuli Venezia Giulia in the Last 20 Years
Introduction: Epidemiological study conducted on patients (pts) with neuroendocrine tumors (NEN) at the regional referral center for Endocrinology and Metabolic Diseases of the Udine Hospital, Italy.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof Franco Grimaldi
Keywords: survival